ELISA – Products

Scalable BLI technology is a powerful screening approach, providing scientists a highly versatile tool in the field of label-free interaction analysis. The use of this microfluidic-free technology increased rapidly, and the trend is upwards, as BLI continues to gain widespread acceptance and diversifies its application base.

Enzyme Linked Immunosorbent Assays (ELISAs) are commonly used to quantify biomarkers in serum, plasma and cell culture supernates. These samples contain a variety of factors that can interfere with ELISA results, commonly referred to as a matrix effect. Eliminating these factors is essential to obtaining accurate sample values.

Eliminate the challenges that come with manual ELISAs. Meet Ella™ — your next generation automated ELISA instrument from Bio-Techne. In just 90 minutes you get highly reproducible validated assay data with no manual steps.

Drug product glycosylation is a critical quality attribute (CQA) due to its potential impact on pharmacokinetics properties and stability of the product. The ability to view and choose from desired titer and glycosylation profiles at the same time provides more in-depth knowledge that facilitates more informed decisions.

Selectins are actively involved in constitutive lymphocyte homing, chronic and acute inflammation, and cancer metastasis. Therefore, they are current hot targets for developing therapeutics to treat various diseases, such as sickle cell disease and malignancies.

Download this app note to explore various solutions designed to improve COVID-19 detection and the development of vaccines and therapeutics.

At high levels, host cell proteins (HCPs) can cause immunogenic responses and reduced efficacy of biologics, so it is imperative to have an effective, robust HCP assay to detect them and mitigate these effects.

Sino Biological, Inc. has announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047. A total of 17 million shares were issued for a total of 4.98 billion RMB raised during this initial public offering.